This post was originally published on this site

When Gary Glick, Ph.D. left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.” Scorpion Therapeutics was born. Read more.

The post Scorpion Therapeutics debuts with $108M to ‘put the sting in cancer’ appeared first on Atlas Venture.